These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3755281)

  • 1. Differing response rates and survival between squamous and non-squamous non-small cell lung cancer. Comparison of CAP versus MAP.
    Eagan RT; Frytak S; Creagan ET; Richardson RL; Coles DT; Jett JR
    Am J Clin Oncol; 1986 Jun; 9(3):249-54. PubMed ID: 3755281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy in squamous cell carcinoma of the lung.
    Krzakowski MJ; Swierz J
    Chemioterapia; 1984 Apr; 3(2):75-8. PubMed ID: 6085285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer.
    Krook JE; Jett JR; Fleming TR; Dalton RJ; Marschke RF; Cullinan SA; Windschitl HE; Everson LK; Brunk FS; Laurie JA
    J Clin Oncol; 1985 Jun; 3(6):842-8. PubMed ID: 3839263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group.
    Feld R; Rubinstein L; Thomas PA
    J Natl Cancer Inst; 1993 Feb; 85(4):299-306. PubMed ID: 8381187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer.
    Umsawasdi T; Valdivieso M; Booser DJ; Barkley HT; Ewer M; MacKay B; Dhingra HM; Murphy WK; Spitzer G; Chiuten DF
    Cancer; 1989 Nov; 64(10):1995-2000. PubMed ID: 2553235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized comparative trial of sequential versus alternating cyclophosphamide, doxorubicin, and cisplatin and mitomycin, lomustine, and methotrexate in metastatic non-small-cell lung cancer.
    Eagan RT; Frytak S; Richardson RL; Creagan ET; Therneau TM; Coles DT; Jett JR
    J Clin Oncol; 1988 Jan; 6(1):5-8. PubMed ID: 2826714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of combination chemotherapy programs in advanced adenocarcinoma-large cell carcinoma of the lung: a North Central Cancer Treatment Group study.
    Krook JE; Fleming TR; Eagan RT; Cullinan S; Pfeifle D; Elliott T; Etzell P
    Cancer Treat Rep; 1984 Mar; 68(3):493-8. PubMed ID: 6322987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer.
    Cartei G; Cartei F; Cantone A; Causarano D; Genco G; Tobaldin A; Interlandi G; Giraldi T
    J Natl Cancer Inst; 1993 May; 85(10):794-800. PubMed ID: 8387607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update in cancer chemotherapy, Part III: Lung cancer, Part 1.
    Wright JC
    J Natl Med Assoc; 1985 Oct; 77(10):815-27. PubMed ID: 2414458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma.
    Lele SB; Piver MS
    Gynecol Oncol; 1989 Apr; 33(1):6-8. PubMed ID: 2467845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy for extensive non-small cell carcinomas of the lung.
    Davis S; Rambotti P; Park YK
    Cancer Treat Rep; 1981; 65(11-12):955-8. PubMed ID: 7028257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of chemotherapy in non-small cell lung cancer: the community perspective.
    Folman RS; Rosman M
    Semin Oncol; 1988 Jun; 15(3 Suppl 4):16-21. PubMed ID: 2839903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective randomized trial.
    Tomirotti M; Perrone S; Giè P; Canaletti R; Carpi A; Biasoli R; Lombardi F; Giovanninetti A; Mensi F; Villa S
    Tumori; 1988 Oct; 74(5):573-7. PubMed ID: 3217992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bronchial arterial infusion chemotherapy with or without radiotherapy for advanced lung cancer].
    Huang DP
    Zhonghua Zhong Liu Za Zhi; 1990 May; 12(3):216-8. PubMed ID: 2249598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study.
    Valdivieso M; Burgess MA; Ewer MS; Mackay B; Wallace S; Benjamin RS; Ali MK; Bodey GP; Freireich EJ
    J Clin Oncol; 1984 Mar; 2(3):207-14. PubMed ID: 6321689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study.
    Alberts DS; Kronmal R; Baker LH; Stock-Novack DL; Surwit EA; Boutselis JG; Hannigan EV
    J Clin Oncol; 1987 Nov; 5(11):1791-5. PubMed ID: 2445932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Benefits of cisplatin-based polychemotherapy in non-small cell bronchogenic carcinoma. Kyushu Lung Cancer Chemotherapy Study Group].
    Ohta M; Hara N; Ichikawa Y; Kanda T; Shima K; Tamura K; Hokama M
    Gan To Kagaku Ryoho; 1988 Jun; 15(6):1901-8. PubMed ID: 2454615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer.
    Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Sasaki Y; Fujita J; Futami H
    Cancer Treat Rep; 1985 Sep; 69(9):945-51. PubMed ID: 2992785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of combination cyclophosphamide, doxorubicin and cisplatin (CAP) chemotherapy in advanced non-small-cell lung cancer.
    Rosell Costa R; Abad-Esteve A; Roig Cutilles J; Solorzano IM; Fernandez Marcial C; Ribas Mundo M
    Tumori; 1987 Aug; 73(4):345-9. PubMed ID: 3660472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.